Therapeutic Areas

Precigen Portfolio

Therapeutic Area Asset Platform Indication
Phases
Discovery
Preclinical
Phase 1
aba

Immuno-Oncology

PRGN-3008

UltraCAR-T

Undisclosed

b

Preclinical

ccd

Autoimmune Disorders

PRGN-3009

Undisclosed

Undisclosed

a

Discovery

abd

Immuno-Oncology

PRGN-2010

AdenoVerse Vaccine

Solid Tumors

b

Preclinical

  • A Phase 1 study of PRGN‐3005 UltraCAR-T, an investigational therapy using autologous chimeric antigen receptor T (CAR-T) cells for treatment of patients with advanced-stage platinum-resistant ovarian cancer patients.

aaa

Immuno-Oncology

PRGN-3005

UltraCAR-T

Solid Tumors

c

Phase 1

  • A Phase 1/1b study of PRGN-3006 UltraCAR-T, an autologous chimeric antigen receptor T-cell (CAR-T) therapy, for treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS).

aaa

Immuno-Oncology

PRGN-3006

UltraCAR-T

AML, MDS

c

Phase 1

aba

Immuno-Oncology

PRGN-3007

UltraCAR-T

Undisclosed

b

Preclinical

abd

Immuno-Oncology

PRGN-5001

Multifunctional Therapeutic

Solid Tumors

b

Preclinical

acd

Immuno-Oncology

PRGN-5002

Multifunctional Therapeutic

Solid Tumors

a

Discovery

abd

Immuno-Oncology

PRGN-2009

AdenoVerse Vaccine

Solid Tumors

b

Preclinical

  • A phase 1 safety study of adoptive cellular therapy using autologous T cells transduced with lentivirus to express a CD33 specific chimeric antigen receptor (CAR) in patients with relapsed or refractory CD33-positive acute myeloid leukemia.

    Please visit clinicaltrials.gov for additional information regarding this clinical study.

aab

Immuno-Oncology

INXN-3004

Viral CAR-T

AML

c

Phase 1

acd

Immuno-Oncology

PRGN-2011

AdenoVerse Cytokine Therapy

Solid Tumors

a

Discovery

bbd

Infectious Diseases

PRGN-2012

AdenoVerse Vaccine

Undisclosed

b

Preclinical

bbd

Infectious Diseases

PRGN-2013

AdenoVerse Vaccine

Undisclosed

b

Preclinical

ccd

Autoimmune Disorders

PRGN-3010

Undisclosed

Undisclosed

a

Discovery

Pipeline as of February 2019

Emerging Therapeutics

Precigen explores emerging therapeutics when there is strategic alignment with the company’s core expertise and potential for patient benefit.

Emerging Therapeutics
Emerging therapy in otology

Precigen and Novartis are collaborating on CGF166, a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1). CGF166 is currently under clinical investigation to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through IL-infusion to improve hearing. Please visit clinicaltrials.gov for additional information regarding this clinical study.